Key Highlights
- Revenue of USD 18.96 million missed the USD 20.00 million estimate, while loss per share was USD 0.13.
- Revenue fell 8% year over year, and gross Margin was 64.9% against 67.5% a year earlier.
- A USD 17 million cost reduction plan began on September 1, and general and administrative expense fell 24%.
- Cash was USD 22.7 million, and the filing includes a Going Concern note tied to a Credit agreement covenant.
TELA Bio (NASDAQ:TELA), a soft tissue reconstruction company, reported third quarter 2026 Revenue of USD 18.96 million, below the USD 20.00 million estimate. Loss per share of USD 0.13 was narrower than the estimated USD 0.16 loss. Revenue fell 8% from USD 20.7 million a year earlier, and nine-month revenue was USD 57.3 million against USD 59.4 million, a decrease of 4%.
Management, led by a chief executive in her 90th day, said U.S. revenue was USD 15.4 million and European revenue was USD 3.6 million. It said the decrease was driven by a USD 2 million decline in OviTex PRS, partly offset by growing international sales.
Product Mix and Cost Plan
OviTex PRS revenue fell 20% year over year and 6% sequentially. Management said U.S. hernia revenue rose slightly from the prior quarter and that LIQUIFIX set a quarterly sales record, with its customer base up 60% year to date. European revenue grew 18%. Management said it expects the gap between the product lines to keep narrowing as year-over-year comparisons stabilize the mix. The company also announced FDA 510(k) clearance of the Liora Monofilament Scaffold.
A USD 17 million cost reduction plan began on September 1. General and administrative expense fell USD 0.9 million, or 24%, to USD 3.0 million, and Research and Development expense fell USD 0.7 million, or 32%, to USD 1.6 million.
Margins, Loss and Going Concern Note
Gross profit fell 12% to USD 12.3 million from USD 14.0 million, and gross margin was 65% against 68%. The filing attributes the decline to lower revenue and a USD 1.0 million write-off of expired inventory. Net loss rose 8% to USD 9.3 million from USD 8.6 million, and nine-month net loss increased USD 3.0 million, or 10%.
Cash and cash equivalents were USD 22.7 million at September 30 against USD 50.8 million at year end. The filing reports negative Working Capital of USD 28.3 million due to a Debt reclassification and an accumulated Deficit of USD 430.4 million. It states that management concluded substantial doubt exists about the company's ability to continue as a going concern, citing the ability to comply with a revenue covenant under its credit agreement, and that it is pursuing actions including seeking a Waiver or amendment.
Legal Disclosure and Items to Follow
The filing's Legal Proceedings item states the company is not currently subject to any material legal proceedings. The items to follow are covenant compliance, the cost plan's effect on spending, OviTex PRS trends, European growth and the cash balance.






Please wait processing your request...